Trulance

Quick links to important sections

Trulance

Treatment option:

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Trulance

What is Trulance?

Trulance is a prescription medication used to treat specific types of chronic gastrointestinal conditions. It contains the active ingredient plecanatide, which is a guanylate cyclase-C (GC-C) agonist.

Mechanism of Action

Plecanatide is a structural analog of human uroguanylin, a naturally occurring peptide in the body. It works locally within the upper gastrointestinal tract to mimic the effects of this peptide.

When the medication binds to GC-C receptors on the surface of the intestinal lining, it triggers a series of biochemical processes:

  • Fluid Secretion: It stimulates the secretion of chloride and bicarbonate into the intestinal lumen.
  • Hydration: The increase in ions draws water into the intestines, which helps to soften the stool.
  • Transit: By increasing fluid volume, the medication promotes more frequent bowel movements and reduces the time it takes for waste to pass through the digestive system.

Therapeutic Use

Trulance is primarily utilized for the management of the following conditions in adults:

  • Chronic Idiopathic Constipation (CIC): A condition characterized by persistent difficulty passing stool or infrequent bowel movements with no known physical or physiological cause.
  • Irritable Bowel Syndrome with Constipation (IBS-C): A functional gastrointestinal disorder where constipation is accompanied by chronic abdominal pain and bloating.

What side effects are possible with Trulance?

Possible Side Effects and Safety Information

The safety profile of Plecanatide (Trulance) is concentrated primarily in the gastrointestinal system, consistent with its targeted, local action within the intestines. This information is structured based on classifications found in official regulatory documents from governmental health authorities.


Frequency-Classified Adverse Reactions

The most frequently reported adverse reaction is Diarrhea, which is classified in regulatory labeling as a Very Common effect (occurring in 1 out of 10 people or more). Less frequent reactions, often classified as Common, may include other gastrointestinal events and certain infections.

System-Organ Class Common Adverse Reactions
Gastrointestinal Disorders Abdominal Distension, Flatulence, Abdominal Pain
Infections and Infestations Gastroenteritis, Upper Respiratory Tract Infection

Serious Adverse Reactions and Safety Constraints

Official labeling documents Severe Diarrhea as a serious adverse reaction, which, if it occurs, necessitates the suspension of the medicine. This reaction is reported to occur most often early in the course of treatment, generally within the first four weeks.

Safety is subject to explicit restrictions concerning specific patient populations and conditions:

  • Pediatric Contraindication: The medicine is contraindicated in children under 6 years of age due to the serious risk of dehydration documented in nonclinical studies. Use should also be avoided in children aged 6 to less than 18 years.
  • Gastrointestinal Restriction: It is contraindicated in any patient with a known or suspected mechanical gastrointestinal obstruction.

No dose adjustment is specified in regulatory documents for patients with mild to moderate renal or hepatic impairment, consistent with the drug's minimal systemic absorption.

Overdose and Emergency Response

Overdose and when to seek help

The official regulatory documents specify that an overdose of plecanatide primarily results in an exaggeration of the drug's intended local effect on the digestive system. The most critical documented presentation of an overdose is severe diarrhea. Overdose management is defined by regulatory authorities as supportive care, with the critical focus being the counteraction of severe fluid loss. No specific antidote is known or available for plecanatide overdose.

Documented Manifestation Required Regulatory Action
Severe Diarrhea Suspend Trulance dosing immediately.
Suspected Overdose Contact a regional poison control centre for management guidance.

Urgent medical attention must be sought immediately for a suspected overdose, particularly if symptoms escalate to include signs of serious dehydration, collapse, or difficulty breathing. Supportive care must prioritize the restoration and maintenance of fluid and electrolyte balance.

A significant population-specific risk is documented: the medicine is strictly contraindicated in children younger than 6 years of age and its use is avoided in patients aged 6 to less than 18 years. This restriction is due to the explicit, documented potential for serious dehydration in these age groups.

Therapeutic Uses of Trulance

The medication is considered relevant for managing conditions such as Chronic Idiopathic Constipation (CIC) and Irritable Bowel Syndrome with Constipation (IBS-C) in adults. This provides context for the therapeutic domains where the medicine is applied.


Easing Symptomatic Discomfort

This medicine is applied across domains where additional symptomatic support is needed, addressing symptoms related to physical discomfort that often interfere with daily functioning. It provides supportive relief when symptoms become more noticeable and may help patients cope more steadily with symptom fluctuations.

“This approach supports the patient during difficult episodes by easing distress.”

Quick Fact: Supports Management of Symptoms that Interfere with Daily Functioning


Managing Episodic and Acute Symptoms

The medicine is relevant for conditions involving episodic or fluctuating manifestations, where symptoms associated with acute or episodic changes create noticeable physiological strain. It is commonly used when symptoms intensify and short-term symptomatic assistance is needed, assisting with easing the overall symptom burden during symptomatic periods and phases of heightened discomfort.

Eligibility and Restrictions for Use

Who Can and Cannot Use Trulance?

Regulatory documentation strictly defines the eligible population for Trulance (plecanatide) by age and certain pre-existing conditions.

Contraindications and Restricted Use

The medicine is contraindicated (must not be used) in two primary patient populations:

  • Pediatric patients less than 6 years of age due to the serious risk of dehydration.
  • Patients with known or suspected mechanical gastrointestinal (GI) obstruction.

Use is strongly avoided in pediatric patients aged 6 years to less than 18 years because the safety and effectiveness in this age group have not been established by regulatory authorities.


Eligibility Status by Population

Population Category Regulatory Eligibility Status
Approved Age Group Adults 18 years of age and older
GI Obstruction Contraindicated
Age < 6 years Contraindicated
Age 6 to < 18 years Avoid Use (Safety not established)
Renal/Hepatic Impairment No dose adjustment required
Pregnancy Maternal use is not expected to result in fetal exposure (data insufficient)
Lactation Unknown if distributed in human milk (potential risk of serious adverse effects to infant)

What should I know about interactions with other medicines?

Interactions with other medicines and products

The official interaction profile for Trulance (Plecanatide) is structured around the drug's limited systemic exposure. Regulatory documents, including FDA Prescribing Information, state that the active ingredient and its active metabolite are not measurably detected in plasma at therapeutic doses. This characteristic fundamentally informs the drug's interaction profile.

Systemic Pharmacokinetic Interactions

Systemic drug-drug interactions are not expected due to the negligible systemic availability of Plecanatide. Official regulatory data confirms that the drug and its metabolite do not inhibit or induce major CYP450 enzymes, such as CYP2C9 and CYP3A4, nor do they interact with key drug transporters like P-glycoprotein (P-gp) or Breast Cancer Resistance Protein (BCRP). This absence of systemic activity means that no dosage adjustments or administration separation rules are documented based on metabolic or transporter interactions.

Pharmacodynamic and Food Interactions

The only documented interaction is a potential additive pharmacodynamic effect. Co-administration with other laxative-type products may increase the potential for the adverse reaction of diarrhea. Official labeling does not list any specific contraindicated drug combinations. Regarding administration timing, the drug may be taken with or without food, and no specific interactions with alcohol or herbal products are documented in regulatory prescribing information.

Mechanism of Action

Trulance (Plecanatide) is a selective agonist that acts directly on the Guanylate Cyclase-C (GC-C) receptor, an enzyme located on the apical surface of intestinal epithelial cells. This localized interaction initiates an intracellular signaling cascade that rapidly elevates the concentration of cyclic Guanosine Monophosphate (cGMP) within the cell. The subsequent rise in cGMP levels directly regulates the Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) ion channel.

Activation of the CFTR channel enhances the secretion of chloride and bicarbonate ions from the cells into the intestinal lumen. This efflux of electrolytes creates a strong osmotic gradient, causing water to be passively drawn into the gut to maintain electrochemical balance. The biological consequence of this increased fluid volume is the hydration and softening of intestinal contents, which physically accelerates the speed of gastrointestinal transit through the colon.

Dosage and Administration Information

How to Use Trulance (Plecanatide) Tablets

Trulance is an oral medication that must be used exactly as prescribed by a healthcare provider. The instructions for administration are outlined below.

Official Dosing and Timing

Administration Detail Official Guideline
Recommended Dose One 3 mg tablet once daily.
Route of Administration Oral.
Timing (Meals) May be taken with or without food.
Age Group Approved for use in adults (18 years of age and older).

Preparation and Administration Procedures

Swallow the tablet whole for each dose. Do not chew or break the tablet unless specifically preparing it for alternative administration, as outlined below.

If a dose is missed: Skip the missed dose entirely and take the next dose at the regular scheduled time. Do not take two doses at the same time to compensate for a missed dose.

For patients unable to swallow the whole tablet: The tablet may be crushed and mixed with water or applesauce, or administered via a feeding tube. The instructions for alternative administration are:

  • Oral Administration in Water: Place the tablet in a clean cup with approximately 30 mL (1 ounce) of room temperature water. Swirl gently for at least 10 seconds until the tablet falls apart, and swallow the entire mixture immediately. A second 30 mL rinse should be swallowed to ensure the full dose is taken.
  • Oral Administration in Applesauce: Crush the tablet into a powder and mix it with 1 teaspoon of room temperature applesauce in a clean container. Consume the entire mixture immediately.
  • Administration via Nasogastric or Gastric Feeding Tube: Mix the tablet with 30 mL of water and administer immediately via the flushed tube. Flush the tube with at least 10 mL of additional water after administration.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Trulance


Evidence for use in Chronic Idiopathic Constipation (CIC)

Trulance was studied in research contexts involving Chronic Idiopathic Constipation (CIC), a condition characterized by fluctuating or episodic manifestations. Research examined how this drug was associated with changes in outcomes related to physical discomfort and outcomes related to stool frequency for people living with CIC. These studies were designed to evaluate patterns of symptom change over defined time intervals.

Types of Studies in CIC

The primary research for CIC involved trials where participants either received Trulance or an inactive substance (placebo). These studies were used in research exploring how symptoms change over time and typically focused on relevant in trials assessing short-term or episodic symptom patterns. The data show patterns related to changes in patient-reported outcomes describing perceived discomfort for some participants in the Trulance groups compared to the placebo groups.


Evidence for use in Irritable Bowel Syndrome with Constipation (IBS-C)

Trulance was evaluated in research exploring its use for Irritable Bowel Syndrome with Constipation (IBS-C). This is a condition where symptoms may vary in intensity and often involves outcomes related to systemic or functional imbalance. The studies monitored whether Trulance was associated with changes in both outcomes related to physical discomfort (abdominal pain) and outcomes related to stool frequency, which are key outcomes reflecting daily functioning or activity level in IBS-C. The findings indicate that Trulance was associated with changes in these combined IBS-C outcomes describing episodic or acute changes for some individuals in the studies. However, findings were mixed when looking at all participants, and results apply only to the populations studied.


Long-term Studies and Follow-up

Research has explored what was observed in the studies beyond the initial short-term study periods. This is critical for understanding the patterns observed over defined time intervals in a condition marked by functional limitations over time. However, the follow-up durations were limited in many cases, and long-term effects are not fully established. Research is ongoing to provide more context about the extended use of Trulance.


Evidence in Special Populations

Research examined the use of Trulance in certain patient groups, such as older adults. For many other groups—such as children, pregnant-related populations, or those with various comorbid conditions—the data for certain groups remain insufficient. This means that evidence is limited for these specific special populations, and the established results apply only to the populations studied in the major trials.

Frequently Asked Questions (FAQ)

Common questions about Trulance (FAQ)

Q: Can I crush or split the Trulance tablet if I have trouble swallowing pills?

A: Official administration instructions outline specific procedures for crushing the Trulance tablet and mixing it with water or applesauce. This method is provided for adult patients who may have difficulty swallowing the whole tablet. The instructions note that the prepared mixture should be consumed immediately to maintain the dose’s stability and quality.

Q: Can I drink alcohol while taking Trulance? (Informational only)

A: Regulatory documents do not list any specific interactions with alcohol. This is consistent with the drug's properties, as Trulance is minimally absorbed into the bloodstream and therefore not expected to interact with substances that are processed systemically.

Q: Why is diarrhea often listed as a side effect of Trulance?

A: Diarrhea is the most common side effect reported in clinical trials for Trulance. This is consistent with the drug's intended mechanism of action, which involves increasing the flow of fluid and water into the intestine to help contents move through the colon.

Q: Does taking Trulance affect the absorption of other medications?

A: Systemic interactions with other medicines are not expected because Trulance and its active components are negligibly absorbed into the bloodstream. Official information indicates that the drug does not interfere with the major enzyme systems responsible for processing most other medications in the body.

Q: What if I am already taking several other medications—is Trulance still an option?

A: Due to its minimal systemic absorption, Trulance is not expected to interfere with the way most other medicines are metabolized. However, official information notes that combining it with other laxative-type products may result in an additive effect, which could increase the potential for diarrhea.

Q: How long does it typically take to notice the effects of Trulance?

A: Clinical trials used to study Trulance measured key changes in symptoms over a treatment period of 12 weeks. While patient response varies, the most common side effect, diarrhea, was reported to occur most often within the first four weeks of starting treatment.

Q: Is it okay to take Trulance on an empty stomach?

A: According to official administration instructions, Trulance may be taken with or without food.

Q: Are headaches a common side effect reported with Trulance?

A: Headaches are not listed among the most common adverse reactions reported in the major clinical trials. Common adverse reactions are defined as those occurring in 2% or more of patients and more often than with placebo.

Q: What are the most serious side effects I should be aware of?

A: The most serious safety concerns identified in regulatory documents include a Boxed Warning regarding the potential for severe dehydration in pediatric patients under age six. Additionally, the development of Severe Diarrhea is considered a serious adverse reaction, and regulatory information states that the medicine must be suspended if this occurs.

Q: Does Trulance interact with common over-the-counter pain relievers like ibuprofen?

A: Systemic interaction with common over-the-counter pain relievers like ibuprofen is not expected. This is because Trulance is minimally absorbed into the bloodstream and does not affect the major enzymes that process these types of medications.

Q: Are there any known interactions between Trulance and supplements or vitamins?

A: Specific interactions with most vitamins or supplements are not documented in the official prescribing information. The minimal absorption of Trulance into the bloodstream suggests that systemic interactions are generally not anticipated.

Q: What happens in the body when Trulance starts working?

A: When Trulance starts working, it acts locally on specific receptors in the intestine. This action increases the secretion of fluid and water into the bowel, which helps to soften the stool and accelerate transit time.

Q: How often do people stop taking Trulance due to side effects?

A: Studies indicate that only a small percentage of participants stopped taking Trulance due to adverse effects. Clinical trial data showed that discontinuation rates due to adverse reactions, primarily diarrhea, ranged between 2.5% and 4.5% across the major studies.

Q: Will Trulance cure my constipation permanently?

A: Official documentation indicates that Trulance is a treatment intended for chronic idiopathic constipation and irritable bowel syndrome with constipation in adults. The medicine is not described as a permanent cure for these chronic conditions.

Q: Are there any restrictions on driving or operating machinery while taking Trulance?

A: The official prescribing information does not list any warnings or precautions related to impaired ability to drive or operate machinery. This is consistent with the drug's minimal absorption into the bloodstream and its safety profile.

Q: Does the research evidence show Trulance works equally well for all patients?

A: Research evidence shows that not all patients respond in the same way to Trulance. Clinical trial data indicates that a specific percentage of participants met the defined response criteria, suggesting that individual effectiveness may vary among the study population.

Q: What is the likelihood of experiencing severe stomach pain while on Trulance?

A: Abdominal pain is listed as a common adverse reaction in clinical trials. It is important to note that abdominal pain is also a key symptom of the conditions Trulance is intended to address, such as Irritable Bowel Syndrome with Constipation.

Q: Can men and women expect different results from Trulance?

A: Clinical pharmacology studies did not indicate that a dose adjustment is necessary based on gender. This suggests that men and women showed similar patterns of systemic exposure and dose requirements in studies.

Q: Is it normal to have some stomach rumbling after starting Trulance?

A: The official labeling lists Flatulence and Abdominal Distension as common adverse reactions in clinical trials. These types of gastrointestinal events are often related to digestive noises or discomfort.

Q: Does Trulance require a special diet to be effective?

A: The official instructions for use state that Trulance may be taken with or without food. No specific dietary requirements are documented in the regulatory information for the medicine to be effective.

Q: Are there specific symptoms that mean Trulance is not the right medicine?

A: Trulance is contraindicated in patients under six years old and those with a known or suspected mechanical gastrointestinal obstruction. Additionally, the development of Severe Diarrhea is considered a serious adverse reaction, and regulatory information states that the medicine must be suspended if this occurs.

Q: Has Trulance been studied in patients with liver or kidney issues?

A: Clinical pharmacology studies have shown that due to the medicine's minimal absorption into the body, no dose adjustment is required for adult patients with mild to moderate renal or hepatic impairment.

Q: Do you need to continuously increase the dose of Trulance over time?

A: The approved prescribing information recommends a fixed dose for both chronic idiopathic constipation and IBS-C. No provision for a continuous dose increase or escalation is included in the official regulatory documentation.

How should Trulance be stored and disposed of?

How to Store and Dispose of Trulance

This medication must be stored according to strict regulatory guidelines to maintain its effectiveness and ensure safety.

Storage Requirements

Condition Requirement
Temperature Store at controlled room temperature, between 68 F and 77 F (20 C to 25 C). Do not freeze.
Protection Keep the tablets in the original container, tightly closed, to protect from moisture, heat, and light. The desiccant packet must remain inside the bottle.
Child Safety Keep the medication out of sight and reach of children and store it in a secure location.

Handling and Stability

If the tablet is crushed and mixed with applesauce or water, the prepared mixture must be consumed immediately and should not be stored for later use. This ensures the correct stability and quality of the dose.

Disposal Instructions

Safely throw away any medicine that is expired or no longer needed. Consult a healthcare professional or pharmacist for specific local advice on proper disposal methods, such as drug take-back programs.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Equivalent of Trulance found in:

A-Z Index: